CAR T-cell therapy (St Louis University/MaxCyte)

N/A

Report date: 2025/01/26 19:05:34

Base Information

Drug NameCAR T-cell therapy (St Louis University/MaxCyte)

Drug Alias Namechimeric antigen receptor modified T cells (St Louis University/MaxCyte)

ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Chimeric antigen receptor T cell therapyBiologics > Protein drugs > Recombinant protein > Fusion protein

Mechanisms of ActionT lymphocytes stimulantsImmunostimulants

TargetsUpdating

Therapy Area/IndicationsHematologic Neoplasms

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryUnited States

CombinationsNo

Global Highest StatusPreclinical

Highest Status in ChinaN/A

Originator CompaniesWashington University

China Registration ClassN/A

Develop Information

Active CompaniesWashington University Maxcyte Inc

Inactive CompaniesN/A

Active IndicationsHematologic Neoplasms

Inactive IndicationsN/A

Other Information

ATC CodeN/A